Stockscreener 앱 받기
58.22
3.91%
-2.37
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.18% on May 1: Drivers Behind the Movement - TradingKey
Bristol-Myers Loses Venue Fight to Texas in Plavix Litigation - Bloomberg Law News
Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript - Insider Monkey
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q1 2026 Earnings Call Highlights: - GuruFocus
Is Bristol Myers Squibb (BMY) Still Attractively Priced After Its Strong 1 Year Share Price Gain - simplywall.st
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMO raises Bristol-Myers Squibb stock price target on Eliquis beat - Investing.com Canada
SIIT U.S. Managed Volatility Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - MarketBeat
Is Bristol-Myers Squibb Co (BMY) Overvalued After 5.2% Rally? GF - GuruFocus
Bristol-Myers Squibb (BMY) Reports Solid Q1 2026 Results with Po - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday? - Benzinga
Bristol Myers (BMY) Q1 2026 Earnings Transcript - The Motley Fool
MSN Money - MSN
INTECH INVESTMENT MANAGEMENT LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales - Reuters
Bristol Myers Squibb Surpasses Profit Expectations: Eliquis and Cancer Medicines Drive Growth - Devdiscourse
PUTNAM GLOBAL HEALTH CARE FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb jumps after Q1 results and reaffirmed 2026 outlook - Quiver Quantitative
Bristol Myers Q1 2026 slides: growth portfolio drives revenue beat - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by Verity Asset Management Inc. - MarketBeat
Crohn’s Disease Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd - Barchart.com
Bristol Myers (BMY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales - WNWN-FM
Bristol-Myers Squibb (BMY) Reports Strong Q1 2026 Earnings, Beats Expectations - GuruFocus
BMS beats estimates and reaffirms guidance - The Pharma Letter
Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK
Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio - ChartMill
Krazati's colorectal cancer approval in jeopardy | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Bristol Myers Squibb (BMY) Q1 2026: EPS $1.31 Beats $1.19 Est., - GuruFocus
Bristol-Myers Squibb Company Stock (US0897961004): Q1 Revenues Rise 3% to $11.5 Billion - AD HOC NEWS
BRISTOL-MYERS SQUIBB ($BMY) Releases Q1 2026 Earnings - Quiver Quantitative
EDGAR Filing Documents for 0000014272-26-000008 - SEC.gov
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook By Investing.com - Investing.com India
Bristol Myers: Q1 Earnings Snapshot - KTVB
Bristol Myers Squibb (NYSE: BMY) posts Q1 2026 results, reaffirms 2026 guidance - Stock Titan
Bristol Myers Squibb Reports First Quarter Financial Results for 2026 - The Joplin Globe
Bristol Tops Estimates on New Drugs Ahead of Key Trial Results - Bloomberg.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
Bristol-Myers earnings ahead: Can new drugs offset legacy slide? By Investing.com - Investing.com Nigeria
Bristol-Myers Squibb (BMY) Set for Earnings Decline Amid Positiv - GuruFocus
Fagan Associates Inc. Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb (BMY)? - simplywall.st
Bristol Myers, Medtronic, Gilead: Top Dividend Healthcare Stocks in April 2026News and Statistics - IndexBox
Brookstone Value Stock ETF's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMS patents Ikaros family zinc finger protein degradation inducers - BioWorld News
AQR Managed Futures Strategy Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Top Companies in Cancer Therapy MarketRoche, Bristol Myers - openPR.com
Bristol’s $14 Billion Neuroscience Drug Bet Is an Early Letdown - Bloomberg.com
D.A. Davidson & CO. Purchases 28,410 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb Stock Gains 20% Amid 2026 Revenue Outlook - IndexBox
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS - Yahoo Finance UK
Is Bristol Myers Squibb the Best Bargain in Big Pharma? - Yahoo Finance
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield - Yahoo Finance
Bristol-Myers Squibb stock (US1078421011): Why Google Discover changes matter more now - AD HOC NEWS
1.39%
0.62%
자본화:
|
볼륨(24시간):